Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03712904
Recruitment Status : Recruiting
First Posted : October 19, 2018
Last Update Posted : August 20, 2019
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University )

Brief Summary:
This phase II trial studies how well stereotactic body radiation therapy and aflibercept work in treating patients with uveal melanoma. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Aflibercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving stereotactic body radiation therapy followed by aflibercept may work better in treating patients with uveal melanoma.

Condition or disease Intervention/treatment Phase
Uveal Melanoma Radiation: Stereotactic Body Radiation Therapy Biological: Ziv-Aflibercept Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To assess the percentage of patients able to successfully complete their prescribed treatment of radiation and intravitreal ziv-aflibercept (aflibercept) injection (IAI) with an acceptable level of toxicity.

SECONDARY OBJECTIVES:

I. To assess for reduction in the incidence of 2-year rates of radiation maculopathy, radiation papillopathy, functional vision preservation, radiation glaucoma, and to assess 2-year local control and progression-free survival.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Randomized Trial of Stereotactic Radiotherapy (SRT) Followed by Intravitreal Aflibercept Injection for Patients With Ocular Melanoma
Actual Study Start Date : August 9, 2019
Estimated Primary Completion Date : July 13, 2020
Estimated Study Completion Date : July 2021


Arm Intervention/treatment
Experimental: A. Stereotactic body radiation therapy, ziv-aflibercept
Patients undergo stereotactic body radiation therapy over 5 fractions every other week day during days 1-10. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
Radiation: Stereotactic Body Radiation Therapy
Undergo radiation
Other Names:
  • SBRT
  • Stereotactic Ablative Body Radiation Therapy

Experimental: B. Stereotactic body radiation therapy, ziv-aflibercept
Patients undergo stereotactic body radiation therapy as in arm A. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 4 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
Biological: Ziv-Aflibercept
Given IV
Other Names:
  • 724770
  • 862111-32-8
  • AVE0005
  • Eylea
  • Vascular Endothelial Growth Factor Trap




Primary Outcome Measures :
  1. Incidence of grade 3 or higher toxicity according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [ Time Frame: Up to 2 years ]
    Will be determined by patients who experience grade >= 3 toxicity related to stereotactic radiation therapy and/or intravitreal aflibercept. Will be tested using one-sided exact binomial test with alpha 0.05. The two arms will be combined for the primary analysis


Secondary Outcome Measures :
  1. Radiation maculopathy rate defined as ophthalmoscopic detection of macular edema perivascular sheathing [ Time Frame: At 2 years ]
    Will be estimated separately in each arm with the corresponding exact binomial 90% confidence interval.

  2. Radiation papillopathy rate defined as ophthalmoscopic detection of peripapillary encircling nerve fiber layer infarction [ Time Frame: At 2 years ]
    Will be estimated separately in each arm with the corresponding exact binomial 90% confidence interval.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Provide signed and dated informed consent form or have a Legally Authorized Representative (LAR) who can give consent
  • Willing to comply with all study procedures and be available for the duration of the study
  • Must be a candidate for radiation therapy
  • Karnofsky performance status (KPS) >= 60
  • Diagnosed with uveal melanoma either clinically or pathologically on biopsy
  • Uveal melanoma of one eye only
  • Localized uveal melanoma, with no evidence of metastasis
  • Women of childbearing potential must have a negative urine or serum pregnancy test within 14 days prior to enrollment

Exclusion Criteria:

  • Tumor thickness more than 14 mm as measured by ultrasound
  • Active collagen vascular disease
  • Any contraindication to intravitreal injections including: elevated intraocular pressure, ocular or periocular infection, active intraocular inflammation, or other determined by treating physician
  • Known allergic reactions to components of intravitreal Aflibercept
  • Patients with known hypercoagulable syndromes
  • Prior radiation to the eye or brain
  • Life expectancy less than 6 months
  • Blind in both eyes
  • Patients unable to receive contrast enhanced brain magnetic resonance imaging (MRI)
  • Deaf in both ears
  • Patients have hypersensitivity to intravitreal Aflibercept
  • Patients is on or within 1 month of systemic anti-VEGF treatment
  • Patients who are candidates for brachytherapy
  • Patients for whom enucleation is standard of care
  • Pregnancy or active breastfeeding. Sexually active men or women of childbearing potential who are unwilling to practice adequate contraception prior to the initial dose/start of the first treatment, during the study, and for at least 3 months after the last dose. Adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly

    • Contraception is not required for men with documented vasectomy
    • Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of childbearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03712904


Contacts
Layout table for location contacts
Contact: Wenyin Shi, MD, PhD (215) 955-6702 wenyin.shi@jefferson.edu

Locations
Layout table for location information
United States, Pennsylvania
Sidney Kimmel Cancer Center at Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Wenyin Shi, MD, PhD    215-955-6702    wenyin.shi@jefferson.edu   
Sponsors and Collaborators
Sidney Kimmel Cancer Center at Thomas Jefferson University
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Principal Investigator: Wenyin Shi, MD, PhD Sidney Kimmel Cancer Center at Thomas Jefferson University

Additional Information:
Layout table for additonal information
Responsible Party: Sidney Kimmel Cancer Center at Thomas Jefferson University
ClinicalTrials.gov Identifier: NCT03712904     History of Changes
Other Study ID Numbers: 18P.457
First Posted: October 19, 2018    Key Record Dates
Last Update Posted: August 20, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Uveal Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Eye Neoplasms
Neoplasms by Site
Eye Diseases
Uveal Diseases
Endothelial Growth Factors
Growth Substances
Physiological Effects of Drugs